Monthly Budget Planning: Wegovy vs Mounjaro Dose Costs
Understanding Wegovy vs Mounjaro Doses: Monthly Cost Impact
The fundamental difference between Wegovy and Mounjaro dosing schedules directly affects your monthly treatment budget throughout the escalation period. Wegovy follows a 16-week dose escalation from 0.25mg to 2.4mg maintenance, while Mounjaro requires 20 weeks to reach its maximum 15mg dose. This creates distinct monthly cost patterns that require different financial planning approaches for UK patients.
Wegovy's shorter escalation means reaching the maintenance dose sooner, establishing predictable monthly costs by week 17 at £209.99 for the 2.4mg pen. Mounjaro's extended escalation provides more gradual dose increases but requires longer budget commitment before reaching steady monthly expenses. Both treatments represent long-term financial commitments, as clinical trials demonstrate weight regain when treatment stops.
Wegovy Dose Escalation: Complete Monthly Cost Breakdown
Your Wegovy journey begins with Month 1 at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg during Month 2. Month 3 costs £99.99 for the 1mg dose, followed by £139.99 for 1.7mg in Month 4. From Month 5 onwards, you'll pay £209.99 monthly for the 2.4mg maintenance dose, creating a predictable ongoing expense for your weight management programme.
Our bundle options can provide supply security during escalation, with the Intro Trio covering your first three months for £299.99, eliminating multiple ordering requirements. The DOSE25 discount code for returning customers ensures your maintenance phase remains cost-effective, while our Ultimate Stability Trio provides three months of 2.4mg supply for £649.99, securing consistent treatment availability.
Clinical Evidence Supporting Wegovy vs Mounjaro Dose Effectiveness
The STEP clinical trial programme demonstrates that Wegovy's dose escalation to 2.4mg maintenance supports significant weight management outcomes. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, with STEP 5 showing sustained clinically studied weight loss at 2 years (Wilding et al., NEJM, 2021).
Mounjaro's dual GIP and GLP-1 receptor agonist mechanism operates through different pathways compared to Wegovy's GLP-1-only approach. Both treatments require prescription-only access through clinical assessment, and individual responses may vary significantly based on personal medical history and adherence to lifestyle modifications.
How Wegovy Doses Work Throughout Your Treatment Journey
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Each dose escalation allows your body to gradually adapt to higher semaglutide levels while minimising potential side effects during the adjustment period. The escalation schedule from 0.25mg to 2.4mg is mandatory and cannot be skipped, ensuring optimal tolerance and effectiveness. This gradual approach helps establish sustainable eating patterns while the medication works on brain appetite centres to reduce food cravings. The maintenance dose provides consistent appetite regulation to support long-term weight management goals.
Streamlined Ordering Process for Wegovy vs Mounjaro Doses
Starting your treatment requires completing our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our prescribers review applications within 3 working days (express 24-hour service available), ensuring appropriate dose selection based on your individual circumstances. Once approved, your chosen dose ships via next-day cold-chain delivery to maintain medication integrity throughout transport. Our GPhC-registered pharmacy (#9012878) ensures all prescriptions meet UK regulatory standards while providing ongoing clinical support throughout your treatment journey. Returning customers can reorder using DOSE25 discount with streamlined assessment processes.
Storage and Practical Considerations: Wegovy vs Mounjaro Doses
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable for 6 weeks at room temperature below 30°C once removed from refrigeration, while Mounjaro requires refrigerated storage or maximum 21 days at room temperature. The FlexTouch pen delivery system provides consistent dosing accuracy across all dose strengths from 0.25mg through 2.4mg maintenance. Store unopened pens in your refrigerator at 2-8°C, rotating stock to use oldest pens first throughout your dose escalation schedule. Each pen contains 4 doses for once-weekly administration, making monthly supply planning straightforward regardless of your current escalation stage. This storage advantage makes Wegovy more suitable for travel and lifestyle flexibility compared to Mounjaro's stricter cold-chain requirements.
Budget Planning Strategies for Wegovy vs Mounjaro Dose Escalations
The different escalation timelines between Wegovy and Mounjaro create distinct budget planning requirements that UK patients must consider before starting treatment. Wegovy's 16-week escalation totals approximately £514.96 before reaching maintenance costs, while Mounjaro's 20-week schedule extends initial investment over a longer period. Your annual Wegovy cost at maintenance dose amounts to approximately £2,519.88, assuming consistent 2.4mg dosing throughout the year.
Our bundle options help manage cash flow during escalation periods, with Getting Started bundles covering consecutive months and Stay Steady bundles providing multiple pens of the same dose for extended phases. The DOSE25 returning customer discount applies to all future orders, ensuring predictable ongoing costs once you establish your treatment routine with either option.
Making Your Choice: Wegovy vs Mounjaro Dose Selection Process
Both Wegovy and Mounjaro are available from EverydayMeds, with our clinical team helping determine which treatment aligns with your medical profile, lifestyle requirements, and budget considerations. The choice between semaglutide's GLP-1-only mechanism and tirzepatide's dual GIP/GLP-1 approach depends on individual factors assessed during your clinical consultation. Your prescriber considers your medical history, previous weight management attempts, and potential contraindications when recommending appropriate treatment options. Understanding the complete cost commitment for either choice ensures you can sustain treatment long enough to achieve meaningful outcomes, as both medications require ongoing use to maintain weight management benefits. Our transparent pricing structure and discount codes support long-term treatment adherence regardless of your final selection.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
